2 Headwinds Facing Pfizer Stock Going Into 2026

The past few years have been a challenging ride for (NYSE: PFE). Since the company made history in 2022, when it became the first in the biopharma industry to reach $100 billion in annual sales, it has been pretty much downhill. Although Pfizer has made some moves to turn things around, it still faces challenges heading into 2026 that could prove significant obstacles to its long-term prospects. Let's look into two of them and discuss what they mean for investors considering Pfizer stock.

Pfizer achieved the $100 billion in annual sales milestone thanks to its work in the coronavirus market. The company's vaccine, Comirnaty, and medicine, Paxlovid, were both among the leaders in their niches. Comirnaty continues to generate meaningful sales for Pfizer. Through the first nine months of the year (ended Sept. 28), the vaccine generated $2.1 billion in revenue, representing a 6% increase over the comparable period of the previous fiscal year.

Image source: Getty Images.

Continue reading

Source Fool.com